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Abstract: Etanercept, a subcutaneously administered fully human soluble tumor necrosis 
factor (TNF) receptor, was initially approved for the treatment of psoriasis at a dose of 
25 mg twice weekly in repeated 24-week cycles with the possibility to double the dose in 
the first 12 weeks of the first cycle. During intermittent treatment, patients retain their ability 
to respond to etanercept. Recently, a new dosing schedule of etanercept 50 mg once weekly 
was approved, based on a study in which PASI-75 (75% improvement of Psoriasis Area and 
Severity Index) was achieved by 37% and 71% of patients at week 12 and 24. Another study 
demonstrated a PASI-75 of 57% and 69% in pediatric psoriasis patients receiving etanercept 
0.8 mg/kg (up to 50 mg) once weekly for 12 and 24 weeks respectively, resulting in European 
approval from age 8. Based on recent clinical trials, the antipsoriatic effect of etanercept can be 
markedly increased in combination with acitretin, methotrexate or UVB. The combination 
with acitretin appears attractive because of its non-immunosuppressive and chemopreventive 
properties. Etanercept–methotrexate combination therapy is well established in rheumatologic 
patients. From a long-term perspective, the combination of TNF-inhibitors with phototherapy 
(photocarcinogenesis) or cyclosporine (carcinogenesis, infections) warrants great caution 
however. Finally, combination with topical calcipotriol–betamethasone ointment may increase 
the speed of response to TNF-inhibitors in the first 4 weeks of treatment.
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Introduction
Tumor necrosis factor (TNF) was first identified in the serum of bacillus 
Calmette-Guérin-infected mice treated with endotoxin, as a factor inducing necrosis 
of transplanted tumors.1 TNF is a pro-inflammatory cytokine, produced by different 
cell types including lymphocytes, macrophages and keratinocytes, with pleiotropic 
effects on numerous tissues.2 It is expressed as a membrane-bound trimeric protein 
that is cleaved by TNFα-converting enzyme (TACE) to yield soluble TNF. The actions 
of TNF are transduced via two types of receptors: TNF-RI initiating a cascade of 
caspase activation leading to apoptosis and TNF-RII activating the pro-inflammatory 
transcription factor nuclear factor kappa B (NFκB) through an intracellular signaling 
pathway.2
TNF occupies a pivotal position in the pathogenesis of immune-mediated 
inflammatory disorders of the joints (rheumatoid arthritis), gut (inflammatory bowel 
disease) and skin (psoriasis).2 The central role of  TNF in the pathophysiology of psoriasis 
was however only fully recognized following the observation that psoriasis fully cleared 
in a Crohn’s disease patient receiving the TNF monoclonal antibody infliximab.3Journal of Inflammation Research 2009:2 30
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Indeed, TNF levels are elevated in psoriasis both in the 
serum as in the psoriatic skin itself.4 Moreover, the increase 
of TNF in psoriasis patients correlates with the psoriasis 
area and severity index (PASI) score whereas the reduction 
of TNF is linked to the clinical response.5 Consequently, 
psoriasis was shown to respond very well to the therapeutic 
effect of TNF inhibitors.6–7
Three TNF antagonists are currently approved for the 
treatment of psoriasis: etanercept (a soluble receptor fusion 
protein), infliximab (a mouse-human chimeric monoclo-
nal antibody) and adalimumab (a fully human monoclonal 
antibody).7 Etanercept is a fully human dimeric fusion 
protein, consisting of two extracellular ligand-binding 
domains of the human 75 kDa TNF-receptor linked 
to the Fc portion of human immunoglobulin G1. As a 
TNF-receptor, etanercept competes for TNF with endog-
enous TNF receptors.8 Bioactive TNF can still be released 
to some extent from the relatively unstable TNF/etanercept 
complexes (contrasting with the greater stability of TNF/
infliximab complexes).8 Therefore etanercept is a less 
potent, more balanced TNF-inhibitor than the antibodies 
infliximab and adalimumab. In contrast to TNF-antibodies, 
etanercept does not have an antigranuloma effect, explaining 
its lack of effectiveness in Crohn’s disease or Wegener’s 
granulomatosis.9–10 At the same time, it does not markedly 
affect the granulomatous defense against intracellular 
bacteria such as Mycobacterium tuberculosis.11 The half-
life of etanercept is 4.3 days, considerably shorter than the 
antibodies. Consequently, etanercept requires more frequent 
administrations but is also eliminated more rapidly in case 
of a serious adverse event (eg, infection).12
Effectiveness of etanercept 
monotherapy in plaque psoriasis
One phase 2 and two phase 3, placebo-controlled clinical 
trials have demonstrated that etanercept is an effective and 
well-tolerated treatment for moderate-to-severe chronic 
plaque psoriasis.6,13,14 The most frequently used endpoint 
is PASI-75, the percentage of patients achieving a 75% 
improvement of their PASI-score, corresponding well to 
the patients reaching a clear or almost clear status.6 The ini-
tially registered dosing schedule for etanercept in psoriasis 
consisted of twice weekly subcutaneous injections of 25 mg 
etanercept for 24 weeks with the possibility of doubling the 
dose (to 50 mg twice weekly) during the first 12 weeks.15 
After each 24-week regiment, another 24-week etanercept 
regimen (25 mg twice weekly) can be started on relapse of 
the psoriasis.15
After 12 weeks of treatment, PASI-75 was achieved 
in 34% in patients receiving 25 mg of etanercept twice 
weekly and in 49% of patients receiving 50 mg twice 
weekly, compared with 3% of patients receiving placebo 
(P  0.001 for both comparisons with the placebo group).13 
After 24 weeks, response rates improved further to 45% 
of patients on 25 mg twice weekly and to 54% in patients 
who had a dose reduction from 50 mg twice weekly the first 
12 weeks to 25 mg the following 12 weeks.13 Similar results 
with etanercept monotherapy in psoriasis were consistently 
shown in another study: PASI-75 was 34% and 49% at 
12 weeks and 44% and 59% at 24 weeks with etanercept 
25 mg twice weekly and 50 mg twice weekly, respectively 
(no stepdown from 50 mg to 25 mg twice weekly occurred 
in this study after 12 weeks).6 Low dose etanercept (25 mg 
once weekly) was clearly less effective with PASI-75 of 
14% and 25% at 12 and 24 weeks respectively.6 An earlier 
phase 2 trial revealed a PASI-75 response of 30% and 
55% with etanercept 25 mg twice weekly at week 12 and 
24 respectively.14 Etanercept was generally well tolerated 
with similar incidence of adverse events in etanercept- vs 
placebo-treated patients with the exception of injection-
site reactions occurring more frequently with etanercept. 
Table 1 Overview of PASI-75 responses to etanercept in different 
dosing schedules and combinations in clinical studies for moderate-
to-severe plaque psoriasis
Dosing schedule  12-week 
PASI-75
24-week 
PASI-75
Reference 
Etanercept monotherapy in adult psoriasis
25 mg once weekly 14% 25% 6
25 mg twice weekly 34%  
34%  
30%  
20%
44%  
45%  
55%  
45%
6  
13  
14  
34
50 mg once weekly 37,5% 71% 25
50 mg twice weekly 12 weeks + 
25 mg twice weekly 12 weeks
– 54% 13
50 mg twice weekly 49%  
49%  
47%  
57%
59% 
–  
60% 
–
6  
13  
23  
22
Etanercept monotherapy in pediatric psoriasis
0.8 mg/kg once weekly  
(max 50 mg)
57% 69% 26
Etanercept combination therapy in adult psoriasis
25 mg once weekly + acitretin 
0.4 mg/kg/day
15% 44% 34
50 mg twice weekly + narrow  
band UvB (thrice weekly)
84,9% 
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Usually, these injection-site reactions were mild and only 
very rarely the reason for withdrawal from the study.6,13,14
Subgroup analysis based on an integrated database of the 
placebo-controlled part (first 12 weeks) of the three afore-
mentioned studies6,13,14 indicated a tendency towards higher 
efficacy in the lower body weight group (below median of 
89.36 kg) and the higher baseline PASI (above median of 16): 
PASI-75 with etanercept 25 mg twice weekly was 41% and 
25% in the lower and higher weight subgroups and 37% and 
29% in the higher and lower PASI-subgroups.16 The influ-
ence of body weight on etanercept effectiveness in psoriasis 
remains however highly controversial as clinical observations 
failed to show any correlation between body mass index and 
etanercept efficacy in psoriasis.17,18 The higher response to 
etanercept in the higher baseline PASI-subgroup16 is probably 
owing to the nonlinear nature of this scoring system with 
lower sensitivity in the lower PASI-range.19
Following etanercept discontinuation in patients who 
exhibited PASI-50 at week 24, a median time to relapse 
(defined as a loss of at least half of the improvement 
achieved between baseline and week 24) of 3 months was 
observed without cases of rebound flare (PASI increasing 
over 150% of baseline).20 Moreover, etanercept retreatment 
of these relapsed patients at the initial dose, generated a 
similar response at 12 weeks indicating that psoriasis patients 
retain clinical response to etanercept on discontinuation and 
retreatment with the drug.20 A recently published long-term 
(54 weeks) study, in which continuous etanercept (25 mg 
twice weekly) therapy was compared with intermittent 
therapy (50 mg twice weekly for maximal 12 weeks or until 
interruption; 25 mg twice weekly on reinitiation), confirmed 
that psoriasis patients continue to respond to etanercept along 
different cycles of discontinuation or reinitiation of the drug.21 
In this study, the physician global assessment (PGA 0 to 
5 score) was used to decide to discontinuation (PGA  2) or 
reintroduction (PGA  3) of etanercept. Compared to PASI, 
PGA is quick and simple to use but its intrarater- and inter-
rater reliability is inferior (intraclass correlation coefficient 
of 81 and 61 for PGA, compared to 96 and 91 for PASI).19 
From baseline to week 54, the mean PASI decreased by 
67,6% and 59,3% in the continuous and intermittent group, 
respectively. PASI-75 data were not disclosed.21
Although no direct head-to-head comparison study of 
etanercept with other TNF-inhibitors is available in psoriasis, 
the antipsoriatic effect of etanercept appears somewhat lower 
and clearly less speedy than that of infliximab and adalim-
umab.7 Very recently, the first head-to-head study of two 
biologics in psoriasis showed that etanercept 50 mg biweekly 
for 12 weeks was less effective than ustekinumab (45 mg 
week 0 and 4), a fully human monoclonal antibody directed 
against the common p40 subunit of interleukin-23 and -12 
(PASI-75 57% and 68% for etanercept and ustekinumab, 
respectively).22
Alternative and new dosing 
schedules
In view of etanercept’s somewhat lower efficacy in psoriasis 
and higher frequency of administration as compared to other 
TNF-inhibitors (infliximab and adalimumab),7 alterna-
tive dosing schedules were developed in order to increase 
effectiveness and/or convenience for the patient.
A first strategy was to maintain a high etanercept dose 
(50 mg twice weekly) for a long-term (beyond the first 
12 weeks). For that purpose, a placebo-controlled trial 
with open-label extension was designed in which patients 
were randomized to receive either placebo or etanercept 
(50 mg) biweekly for 12 weeks. After 12 weeks, patients 
who remained in the study received open-label etanercept 
(50 mg biweekly) for 84 weeks.23 After 12 and 24 weeks, 
47% and 60% of patients displayed a PASI-75 response. 
The PASI-75 response reached its peak at week 48, 
with 63% for the placebo–etanercept group and 61.1% 
for the etanercept–etanercept group. The percentage of 
patients with a PASI-75 response after 96 weeks was 
51.6% for the placebo–etanercept group and 51.1% for 
the etanercept–etanercept group.23 The exposure-adjusted 
event rates were similar for both groups after 96 weeks and 
did not increase with long-term exposure; injection-site 
reactions were more frequent in the etanercept–etanercept 
group. Hence, it was concluded that high-dose long-term 
etanercept is effective and well-tolerated in psoriasis.23 The 
high etanercept dose used in this study (50 mg twice weekly) 
is however not approved beyond the first 12 weeks of treat-
ment of psoriasis.15
A second strategy consisted of the administration of 
high-dose etanercept (50 mg) at a lower frequency (once 
weekly). An open-label extension study of the global 
phase 3 study with etanercept in psoriasis,13 investigated 
the effectiveness of etanercept 50 mg once weekly vs 
25 mg twice weekly for 12 weeks in psoriasis patients who 
had received etanercept 25 mg twice weekly for at least 
24 weeks.24 It was demonstrated that efficacy (maintenance 
of PASI), pharmacokinetic profile (steady-state concentration 
over time, area under the curve and average concentration) 
and safety were comparable between etanercept 25 mg 
twice weekly and 50 mg once weekly.24Journal of Inflammation Research 2009:2 32
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Based on these preliminary findings, a European, 
randomized, double-blind, placebo-controlled study was 
designed to assess the efficacy and safety of etanercept 
50 mg once weekly in 144 moderate-to-severe plaque 
psoriasis patients during 12 weeks.25 In an additional 
12-week, open-label extension phase, all patients received 
etanercept 50 mg once per week. 37,5% of patients receiv-
ing etanercept 50 mg once weekly achieved a PASI-75 
response at week 12, compared to 2.2% of patients in the 
placebo group.25 This PASI-75 response after 12 weeks 
with etanercept 50 mg per week (37,5%) is comparable 
if not slightly higher than that with etanercept 25 mg 
twice weekly at week 12 in the two pivotal phase 3 trials6,13 
and the phase 2 trial14 (34%, 34%, 30%, respectively). At week 
24 following a 12-week open label period with etanercept 
50 mg once weekly, PASI-75 responders further climbed 
to 71,1% in the etanercept–etanercept group (24 weeks 
of etanercept) and 44,4% in the placebo–etanercept group 
(12 weeks of etanercept).25 The 71% PASI-75 response after 
24 weeks etanercept 50 mg once weekly is well above that 
in earlier trials with etanercept 25 mg twice a week (44%, 
45%, 55%)6,13,14 and even 50 mg twice weekly (59, 60%).6,23 
Possible explanations for this “outlier” include the open label 
design (raising high expectations with possibly increased 
“placebo effect” in patients and assessment bias in investiga-
tors in the second part of the study), the lower average body 
weight of the patients (83.4 kg in this European study com-
pared to approximately 90 kg in North-American studies)16 
and the rather high mean baseline PASI in the current study 
(21.4 vs 18.8 in the North-American studies).16 Apart from 
the well-known injection-site reactions, no new safety signals 
were captured.25 In conclusion, the etanercept 50 mg once 
a week treatment regimen was found to be very effective 
and well tolerated in psoriasis; hence, based on these study 
results, regulatory approval of this more patient-convenient 
etanercept dosing regimen (50 mg once weekly) was 
obtained in Europe for the treatment of psoriasis.15
Etanercept in pediatric psoriasis
A recent study evaluated the use of etanercept in 211 children 
and teenagers (aged 4 to 17 years) with moderate-to-severe 
plaque psoriasis (median PASI-score 16.4).26 This was the 
first large study of a systemic drug in pediatric psoriasis. 
Patients were injected once weekly with 0.8 mg/kg of 
etanercept up to a maximum of 50 mg. 57% of etanercept-
treated patients achieved a PASI-75 response at week 12, 
compared to 11% in the placebo group (P  0.001).26 
At week 24, PASI-75 rose to 69%. There were no reports of 
psoriasis rebound or change in psoriasis morphology during 
the withdrawal-retreatment period.26 The higher clinical 
response with etanercept (and placebo) in the pediatric 
population compared to adult psoriasis patients6,13,14,25 may be 
partly explained by the often spontaneously remitting nature 
of pediatric psoriasis; in addition, the weight-based dosing 
of etanercept in children may be more effective than the 
fixed dosing in adults. Four serious adverse events occurred 
in three patients: ovarian cyst removal in one patient, 
gastroenteritis and gastroenteritis-associated dehydration 
in one patient, and pneumonia in one patient. All occurred 
in patients receiving open-label treatment, and all resolved 
without sequelae.26 Skin papilloma (presumably viral warts) 
was an adverse event that was encountered more commonly 
in etanercept-treated patients (16 events) than in the placebo 
group (no events).26 Based on this study, etanercept – as the 
first systemic agent – gained approval for the use of pediatric 
psoriasis from the age of 8 in Europe.15
Etanercept combination  
therapy in psoriasis
Combination therapy is a strategy that can be used to 
increase efficacy in recalcitrant disease (which is rel-
evant for etanercept being the least potent anti-TNF 
medication for psoriasis),7 while reducing the risk for 
cumulative toxicity (eg, by dose reductions). The concept 
of cumulative toxicity is mainly derived from phototherapy 
(photocarcinogenesis) and systemic psoriasis therapies 
(nephrotoxicity for cyclosporine; hepatotoxicity for 
methotrexate). Hence, combination, rotational and sequential 
treatment strategies were developed for classical systemic 
agents for psoriasis.27 Until recently, biologics were thought 
to be spared from cumulative toxicity as they do not cause 
organ toxicity (especially liver and kidney damage). But 
the recent market withdrawal of efalizumab, due to at least 
three cases of progressive multifocal leukoencephalopathy 
in psoriasis patients, all of whom on efalizumab for at least 
3 years, brutally raised awareness about the possible cumula-
tive toxicity of biologics.28 As etanercept is only approved 
in monotherapy for psoriasis,15 its combination with another 
systemic agent represents off-label use.
Topical agents
The use of topical agents (especially vitamin D analogues, 
steroids or a fixed combination of both) in combination with 
phototherapy or systemic drugs for psoriasis is beneficial 
and well documented.27 In clinical practice, topical drugs 
are also very commonly combined with biologics for Journal of Inflammation Research 2009:2 33
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psoriasis, including etanercept.29 Moreover, topical steroids 
of low-to-moderate strength were allowed on distinct 
areas (scalp, axilla, groin) in most of the psoriasis trials 
with etanercept.6,13,22,25,26 An expert consensus conference 
on etanercept treatment of psoriasis recommended the 
use of topical medication in combination with etanercept, 
especially at the start of therapy to increase the speed of 
therapeutic response.30 Nevertheless, formal evidence from 
published clinical trials combining a biologic with a topical 
agent is still very sparse and even lacking for etanercept. 
Very recently, a 16-week randomized controlled study in 
moderate-to-severe chronic plaque psoriasis was conducted 
to assess the efficacy of adalimumab plus calcipotriol–
betamethasonedipropionate fixed-combination ointment vs 
adalimumab plus placebo ointment.31 The vitamin D-steroid 
fixed combination ointment accelerated the response to 
adalimumab during the first 4 weeks of treatment, but did 
not offer benefit beyond 4 weeks compared to adalimumab 
plus placebo ointment.31
Acitretin
Acitretin is a highly interesting candidate for combination 
therapy with biologics as it is not an immunosuppressive 
agent. Moreover, its chemopreventive properties against skin 
carcinogenesis32 are of great value in the high risk moderate-
to-severe psoriasis population, where etanercept (like most 
other systemic psoriasis treatments) appears to increase 
the risk for squamous cell carcinoma.33 A recent Italian 
24-week pilot study on 60 patients with moderate-to-severe 
chronic plaque psoriasis demonstrated that the addition of 
acitretin 0.4 mg/kg/day to etanercept 25 mg once weekly 
was as effective (PASI-75 44%) as etanercept 25 mg 
twice weekly (PASI-75 45%).34 Based on these data, 
acitretin can be viewed as ‘etanercept-sparing’ and cost-
reducing. As the combination of acitretin with etanercept 
at its normal dosing regimen was not performed in this 
trial, it remains unclear whether acitretin is able to bring 
etanercept’s effectiveness to a higher level. A retrospective 
review of 15 psoriasis patients treated with concomitant 
acitretin (10 to 50 mg/day) and biologics (etanercept in 
4 patients) concluded that this scheme was promising for 
the management of refractory psoriasis.35 Similar reports 
on acitretin–etanercept combination in psoriasis were 
described in two case series.29,36 Finally, a stable dose of 
acitretin (50 mg/day) was allowed in a recent study of 
continuous vs paused etanercept therapy of psoriasis21 (see 
section on effectiveness of etanercept monotherapy above 
for a brief outline of this study).
Methotrexate
Etanercept–methotrexate combination therapy is well 
established to increase efficacy in rheumatologic patients 
with insufficient response to monotherapy with either of the 
agents.37 Consequently, psoriasis patients with concomitant 
poorly controlled psoriatic arthritis may benefit from this 
combination. Furthermore, methotrexate can also be combined 
with TNF-antibodies such as infliximab in order to reduce the 
formation of neutralizing antibodies to the TNF-antagonist.38 
A recent Scandinavian 24-week study in 59 psoriasis patients 
with inadequate response to methotrexate monotherapy com-
pared etanercept in combination with a stable methotrexate 
dose with etanercept in combination with a tapered metho-
trexate dose (gradual tapering and discontinuation over the 
first 4 weeks of the trial).39 Etanercept was administered at a 
dose of 50 mg twice weekly the first 12 weeks, followed by 
25 mg twice weekly for the remaining 12 weeks. At week 
24, a significantly higher portion of patients (70%) achieved 
PASI-75 in the group with stable methotrexate dose than in 
the methotrexate-tapered group (37%).39 A case series with 
six psoriasis patients showed that etanercept may be used as 
a means of tapering methotrexate while maintaining good 
clinical control. The patients received methotrexate at a 
starting dose of 10 mg per week with incremental increases 
to achieve a PASI-50 response. Etanercept was then added 
(50 mg/week) and methotrexate tapered by 2.5 mg/week 
every 2 to 4 weeks until discontinued.40 The PASI-50 
response on methotrexate monotherapy was 56.3%. This 
clinical improvement was sustained in 3 of 6 patients after 
discontinuation of methotrexate. Two patients had a relapse 
of psoriasis (loss of at least 50% of PASI improvement) 
when methotrexate was stopped but this was resolved by 
increasing etanercept to 50 mg twice weekly.40 A Dutch case 
series demonstrated that the introduction of methotrexate to 
psoriasis patients with insufficient response to etanercept 
resulted in clear improvement in 4 of 6 patients.41 In addition, 
5 of 6 patients, who were already on methotrexate before the 
introduction of etanercept and who subsequently discontinued 
methotrexate, experienced a decrease in PASI improvement.41 
In the same centre, methotrexate appeared to be the systemic 
agent that was most frequently combined with etanercept.29 
In a recent study of continuous vs paused etanercept therapy 
of psoriasis, patients were allowed to continue a stable dose 
of methotrexate (20 mg/week).21 In the aforementioned 
studies, tolerability of etanercept–methotrexate combination 
was good and there were no signs of increased toxicity on the 
short term.39,40 Long-term safety of etanercept-methotrexate 
combination therapy is obviously a major concern but it is Journal of Inflammation Research 2009:2 34
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reassuring that a 2-year study in more than 500 rheumatoid 
arthritis patients did not reveal increased toxicity (including 
serious infectious and non-infectious adverse events) in the 
etanercept–methotrexate combination group vs etanercept 
or methotrexate monotherapy groups.42
Cyclosporine
Despite the incidental use of cyclosporine–etanercept 
combination therapy in high-need psoriasis patients,29 this 
combination is not recommended from a safety perspective. 
Apart from being an immunosuppressive, cyclosporine also 
induces cancer progression in mice, independently from its 
immune effects.43 These theoretical considerations together 
with the absence of clinical safety data warrant great caution 
for the combination of cyclosporine with TNF-inhibitors 
(including etanercept), which probably bear an increased risk 
for severe infection and malignancy (including skin cancer) 
themselves.33,44,45
Phototherapy
A recently published, multicenter, open-label, single arm 
study investigated the antipsoriatic effect of narrow band-
UVB (thrice weekly) in combination with etanercept (50 mg 
twice weekly) in 86 plaque psoriasis patients. An impressive 
84.9% of patients achieved PASI-75 at week 12.46 Similarly, 
a small, prospective, randomized, half-side study was 
conducted in 5 psoriasis patients who did not exhibit a 
PASI-75 response after 6 weeks of etanercept 50 mg twice 
weekly. A random half-side of the body was treated with 
narrow-band UVB in the next 6 weeks while continuing 
etanercept at an unchanged dose. At week 12, the mean PASI 
reduction (based on half-side PASI) was 89% at irradiated vs 
68% at nonirradiated body side.47
Despite increased efficacy along with a good safety and 
tolerability profile on the short term,46,47 TNF-inhibitor–UVB 
combination therapy raises strong safety concerns from the 
long-term perspective. This vision is based on the highly 
controversial and unclarified role of TNF in epidermal 
carcinogenesis: on the one hand, TNF-knockout mice are 
resistant to chemical skin carcinogenesis48 but at the same 
time TNF is a critical factor for tumor immune surveillance.49 
Indeed, knowing that UV-dependent DNA damage induces 
TNF,50 and that UVB-induced TNF mediates apoptosis in 
keratinocytes51, induction of TNF by UVB may represent a 
mechanism to eliminate mutated (precancerous) cells. This 
view is underscored by the increased risk of squamous cell 
carcinoma in psoriasis patients receiving etanercept.33 Until 
the uncertainty about the role of TNF in photocarcinogenesis 
is fully resolved by preclinical research, it is therefore more 
cautious not to combine TNF-inhibitors with phototherapy.
Conclusion
The initially approved dosing for etanercept in psoriasis 
consisted of 25 mg twice weekly in repeated 24-week cycles 
with the possibility of doubling the dose in the very first 
12 weeks. Recently a new dosing schedule of etanercept 
50 mg once weekly was approved based on a PASI-75 
of 37% and 71% at week 12 and 24. Etanercept was also 
approved in children with psoriasis from the age of 8 at a 
dosing of 0.8 mg/kg (up to 50 mg) once weekly resulting in 
a PASI-75 of 57% and 69% following 12 and 24 weeks of 
treatment. Several small clinical trials and case series have 
shown increased efficacy of etanercept in combination with 
acitretin, methotrexate or UVB, whereas data are lacking for 
the combination with cyclosporine or topical drugs. From a 
safety perspective, the combination with acitretin (nonim-
munosuppressive) or methotrexate (long-term safety data 
in rheumatology) are interesting, whereas the combination 
with cyclosporine or phototherapy holds a theoretical risk 
for increased (photo)carcinogenesis.
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